Should Symptomatic Menopausal Women Be Offered Hormone Therapy?

Rogerio A. Lobo, MD; Serge Bélisle, MD, MSc; William T. Creasman, MD; Nancy R. Frankel, BS, MBA; Neil F. Goodman, MD, FACE; Janet E. Hall, MD; Susan Lee Ivey, MD, MHSA, FAAFP; Sheryl Kingsberg, PhD; Robert Langer, MD, MPH; Rebecca Lehman, MPAS, PA-C; Donna Behler McArthur, PhD, APRN, BC, FAANP; Valerie Montgomery-Rice, MD; Morris Notelovitz, MD, PhD, MB, BCh, FRCOG, FACOG; Gary S. Packin, DO, FACOOG; Robert W. Rebar, MD; MaryEllen Rousseau, CNM; Robert S. Schenken, MD; Diane L. Schneider, MD, MSc; Katherine Sherif, MD; Susan Wysocki, NP

In This Article


The November 2005 ASRM workshop focused on symptomatology in the young, healthy, perimenopausal/menopausal woman. We conclude that young, healthy symptomatic women should be offered the option of hormone therapy. There is clear evidence that hormone therapy improves vasomotor and urogenital symptoms and provides benefits to many women with sexual dysfunction and psychological disturbances related to estrogen deficiency. Taken together, the beneficial effects of hormone therapy for many younger women outweigh the risks and provide an overall improvement in quality of life. Thus, the fears of hormonal therapy in this setting do not seem to be justified. All hormonal therapy should be individualized in symptomatic women. This involves prescribing the regimen and dosage according to individual needs.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.